Kelly Brady
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Kelly Brady
Kelly Brady is recorded as COO at Seres Therapeutics, Inc. (MCRB). Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Kelly Brady was appointed Executive Vice President, Chief Operating Officer, effective March 2, 2026.
“On February 27, 2026, the Board of Directors (the "Board") of Seres Therapeutics, Inc. (the "Company") appointed Richard N. Kender, a current member of the Board, to serve as Executive Chair of the Board and as Interim Chief Executive Officer of the Company, Matthew Henn, Ph.D., the Company's Chief Scientific Officer, to the additional role of President, and Kelly Brady, M.S., the Company's Senior Vice President, Clinical Development, to the role of Executive Vice President, Chief Operating Officer, each effective March 2, 2026 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Seres Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Marella Thorell CEO, CFO, Chief Accounting Officer
- Richard N. Kender CEO, Chairman, Board Member
- Roger J. Pomerantz CEO
- Kelly Brady, M.S. COO
- David S. Ege CTO
- David Arkowitz Chief Accounting Officer
- Eric Shaff Chief Accounting Officer
- Claire Fraser, Ph.D. Board Member
- Claire M. Fraser, Ph.D. Board Member
- Dennis A. Ausiello Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.